Targeted Delivery of BCL-XL Selective Inhibitor Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models
Time: 9:00 am
day: Scientific Program Day Two
Details:
- Understanding how a pre-clinical mechanism-based cardiotoxicity of BCL-XL small molecule inhibitors led to the utilization of an antibody-targeted approach that has potential to differentiate from known platforms
- Reviewing the ADC approach manifested a novel BCL-XL toxicity in kidney
- Considering payload property modification contributed to establishing a TI suitable for clinical dosing
